Wilson Sonsini Goodrich & Rosati advised Acumen Pharmaceuticals on the deal.Acumen Pharmaceuticals, Inc. (Nasdaq: ABOS), a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what…
This content is for Standard 1 Year members only. LoginJoin Now
Author: Martina Bellini
…
This content is for Standard 1 Year members only. LoginJoin Now